---
figid: PMC6141902__js.2018-00180f1
figlink: /pmc/articles/PMC6141902/figure/F1/
number: Figure 1
caption: Schematic of the two commonly activated pathways and genetic aberrations
  involved in thyroid cancer, as well as the targeted therapies studied in thyroid
  cancer. The MAPK and the PI3K pathways are activated by the receptor tyrosine kinase
  (RTK). Increased activity of the receptor tyrosine kinases (purple bars) by growth
  factors, as well as mutations along the pathway, results in oncogenic activation
  of the MAPK pathway, leading to activation of MEK and ERK and, subsequently, tumor
  progression. The PI3K pathway is negatively regulated by PTEN and is activated by
  mutations in PIK3CA, PTEN, AKT, and mTOR. The PI3K pathway can also be activated
  by RAS and NF1 mutations, as there is a cross-talk mechanism with the MAPK pathway.
  TP53 is a tumor suppressor gene and plays a role in apoptosis. TERT activation via
  TERT promotor mutations promotes cell immortality. Patients with TERT promotor mutations
  that coexist with BRAF or RAS mutations have a worse prognosis. In green are drugs
  that can potentially target along these signaling pathways to shrink tumors or halt
  their growth. AKT, protein kinase B.
pmcid: PMC6141902
papertitle: 'Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard
  of Care to Personalized Therapy and Beyond.'
reftext: Sarika N Rao, et al. J Endocr Soc. 2018 Oct 1;2(10):1109-1130.
pmc_ranked_result_index: '15416'
pathway_score: 0.9289283
filename: js.2018-00180f1.jpg
figtitle: The two commonly activated pathways and genetic aberrations involved in
  thyroid cancer, as well as the targeted therapies studied in thyroid cancer
year: '2018'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6141902__js.2018-00180f1.html
  '@type': Dataset
  description: Schematic of the two commonly activated pathways and genetic aberrations
    involved in thyroid cancer, as well as the targeted therapies studied in thyroid
    cancer. The MAPK and the PI3K pathways are activated by the receptor tyrosine
    kinase (RTK). Increased activity of the receptor tyrosine kinases (purple bars)
    by growth factors, as well as mutations along the pathway, results in oncogenic
    activation of the MAPK pathway, leading to activation of MEK and ERK and, subsequently,
    tumor progression. The PI3K pathway is negatively regulated by PTEN and is activated
    by mutations in PIK3CA, PTEN, AKT, and mTOR. The PI3K pathway can also be activated
    by RAS and NF1 mutations, as there is a cross-talk mechanism with the MAPK pathway.
    TP53 is a tumor suppressor gene and plays a role in apoptosis. TERT activation
    via TERT promotor mutations promotes cell immortality. Patients with TERT promotor
    mutations that coexist with BRAF or RAS mutations have a worse prognosis. In green
    are drugs that can potentially target along these signaling pathways to shrink
    tumors or halt their growth. AKT, protein kinase B.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAP2K2
  - AKT2
  - MET
  - MAP2K1
  - FGFR3
  - FGFR1
  - FGFR2
  - AKT1
  - FGFRL1
  - PIK3CD
  - PIK3CG
  - FGFR4
  - AKT3
  - PTEN
  - NF1
  - MTOR
  - MAPK3
  - TP53
  - FLT1
  - FLT4
  - KDR
  - PIK3CB
  - PIK3R4
  - PIK3CA
  - ALK
  - PIK3R3
  - MAPK1
  - HRAS
  - NTRK3
  - EGFR
  - PIK3R5
  - NTRK2
  - TERT
  - PIK3R6
  - NRAS
  - NTRK1
  - RET
  - KRAS
  - lenvatinib
  - cabozantinib
  - sorafenib
  - sunitinib
  - vandetanib
  - crizotinib
  - ceritinib
  - vandetinib
  - pazopanib
  - axitinib
  - vemurafenib
  - dabrafenib
  - selumetinib
  - trametinib
  - combimetinib
  - everolimus
  - temsirolimus
  - thyroid cancer
genes:
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: TP53
  symbol: TP53
  source: hgnc_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: 'ALK:'
  symbol: ALK
  source: hgnc_symbol
  hgnc_symbol: ALK
  entrez: '238'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: 'NTRK:'
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK3
  entrez: '4916'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: 'NTRK:'
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK2
  entrez: '4915'
- word: TERT
  symbol: TERT
  source: hgnc_symbol
  hgnc_symbol: TERT
  entrez: '7015'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: 'NTRK:'
  symbol: NTRK
  source: bioentities_symbol
  hgnc_symbol: NTRK1
  entrez: '4914'
- word: RET
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: lenvatinib
  source: MESH
  identifier: C531958
- word: cabozantinib
  source: MESH
  identifier: C558660
- word: sorafenib
  source: MESH
  identifier: C471405
- word: sunitinib
  source: MESH
  identifier: C473478
- word: vandetanib
  source: MESH
  identifier: C452423
- word: crizotinib
  source: MESH
  identifier: C551994
- word: ceritinib
  source: MESH
  identifier: C586847
- word: vandetinib
  source: ''
  identifier: ''
- word: pazopanib
  source: MESH
  identifier: C516667
- word: axitinib
  source: MESH
  identifier: C503983
- word: vemurafenib
  source: MESH
  identifier: C551177
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: selumetinib
  source: MESH
  identifier: C517975
- word: trametinib
  source: MESH
  identifier: C560077
- word: combimetinib
  source: ''
  identifier: ''
- word: everolimus
  source: MESH
  identifier: C107135
- word: temsirolimus
  source: MESH
  identifier: C401859
diseases:
- word: thyroid cancer
  source: MESH
  identifier: D013964
---
